Země: Velká Británie
Jazyk: angličtina
Zdroj: MHRA (Medicines & Healthcare Products Regulatory Agency)
Morphine sulfate
Napp Pharmaceuticals Ltd
N02AA01
Morphine sulfate
20mg
Modified-release granules
Oral
Schedule 2 (CD)
Valid as a prescribable product
BNF: 04070200; GTIN: 5012854039063
PACKAGE LEAFLET: INFORMATION FOR THE USER _MST_ _®_ _ CONTINUS_ _®_ 20 MG, 30 MG, 60 MG, 100 MG AND 200 MG PROLONGED-RELEASE SUSPENSIONS Morphine sulfate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What _MST CONTINUS _suspension is and what it is used for 2. What you need to know before you take _MST CONTINUS _suspension 3. How to take _MST CONTINUS _suspension 4. Possible side effects 5. How to store _MST CONTINUS _suspension 6. Contents of the pack and other information 1. WHAT _MST CONTINUS _SUSPENSION IS AND WHAT IT IS USED FOR This suspension has been prescribed for you by your doctor to relieve severe pain over a period of 12 hours. It contains the active ingredient morphine which belongs to a group of medicines called strong analgesics or ‘painkillers’. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE _MST CONTINUS_ SUSPENSION DO NOT TAKE _MST CONTINUS _SUSPENSION IF: you are allergic (hypersensitive) to morphine or any of the other ingredients of the suspension (listed in section 6); you have breathing problems, such as obstructive airways disease or respiratory depression. Your doctor will have told you if you have these conditions. Symptoms may include breathlessness, coughing or breathing more slowly or weakly than expected; you have a head injury that causes a severe headache or makes you feel sick. This is because the suspensions may make these symptoms worse or hide the extent of the head injury; you have a condition where the small bowel (part of your gut) do Přečtěte si celý dokument
OBJECT 1 MST CONTINUS SUSPENSION 20 MG Summary of Product Characteristics Updated 20-Mar-2018 | Napp Pharmaceuticals Limited 1. Name of the medicinal product MST ® CONTINUS ® suspension 20, 30, 60, 100 and 200 mg. 2. Qualitative and quantitative composition Each sachet contains Morphine equivalent to Morphine Sulfate 20, 30, 60, 100 and 200 mg. Excipients with known effect: Ponceau 4R (E124) For the full list of excipients, see section 6.1. 3. Pharmaceutical form Prolonged release granules for oral suspension. Pink granules. 4. Clinical particulars 4.1 Therapeutic indications For the prolonged relief of severe and intractable pain. 4.2 Posology and method of administration Posology Adults: A patient presenting with severe pain, uncontrolled by weaker opioids (e.g. dihydrocodeine) should normally be started on 30 mg 12-hourly. Patients previously on normal release oral morphine should be given the same total daily dose as MST CONTINUS suspension but in divided doses at 12-hourly intervals. Increasing severity of pain will require an increased dosage of the suspension. Higher doses should be made, where possible in 30-50% increments as required. The correct dosage for any individual patient is that which is sufficient to control pain with no, or tolerable, side effects for a full 12 hours. It is recommended that the 200 mg strength is reserved for patients who have already been titrated to a stable analgesic dose using lower strengths of morphine or other opioid preparations. Patients receiving MST CONTINUS suspension in place of parenteral morphine should be given a sufficiently increased dosage to compensate for any reduction in analgesic effects associated with oral administration. Usually such increased requirement is of the order of 100%. In such patients individual dose adjustments are required. Paediatric Population: The use of MST CONTINUS suspension in children has not been extensively evaluated. For children with severe cancer pain, a starting dose in the range of 0.2 to 0.8 mg morphine per kg bodyweigh Přečtěte si celý dokument